Lung cancer biopsies are still being done blind more often than you’d think, leading to costly diagnostic errors.
In this episode, Reza Khorasaninejad, Founder & CEO at LEADOPTIK, discusses how advances in photonics and metasurface engineering are enabling highly miniaturized imaging systems for minimally invasive procedures. These innovations aim to address a major challenge in lung cancer biopsies: a lack of imaging guidance that can lead to significant diagnostic errors. Early clinical pilots across multiple sites are demonstrating strong performance, with one hospital already converting into a paying customer. Looking ahead, the company is partnering with Stanford Medicine to develop AI-driven decision support tools to further improve diagnostic accuracy.
Tune in to learn how next-generation imaging and AI are changing that reality and helping physicians hit the right target the first time!
Resources:
Connect with and follow Reza Khorasaninejad on LinkedIn.Follow LEADOPTIK on LinkedIn and explore their website!
Podden och tillhörande omslagsbild på den här sidan tillhör
Saul Marquez. Innehållet i podden är skapat av Saul Marquez och inte av,
eller tillsammans med, Poddtoppen.
